Coenzyme Q10 is an essential cofactor in the respiratory chain and serves as a potent antioxidant in biological membranes. Recent studies in vitro and in vivo provide evidence that Coenzyme Q10 is involved in inflammatory processes and lipid metabolism via gene expression. To study these effects at the epigenomic level, C57BL6J mice were supplemented for one week with reduced Coenzyme Q10 (ubiquinol). Afterwards, gene expression signatures and DNA promoter methylation patterns of selected genes were analysed. Genome wide transcript profiling in the liver identified 1112 up regulated and 571 down regulated transcripts as differ entially regulated between ubiquinol treated and control animals. Text mining and GeneOntology analysis revealed that the "top 20" ubiquinol regulated genes play a role in lipid metabolism and are functionally connected by the PPARα signalling pathway. With regard to the ubiquinol induced changes in gene expression of about +3.14 fold (p≤0.05), +2.18 fold (p≤0.01), and −2.13 fold (p≤0.05) for ABCA1, ACYP1, and ACSL1 genes, respectively, hepatic DNA methylation analysis of 282 (sense orientation) and 271 (antisense) CpG units in the respective promoter islands revealed no significant effect of ubiquinol. In conclusion, ubiquinol affects the expression of genes involved in PPARα signalling and lipid metabolism without changing the promoter DNA methylation status in the liver of mice.
Introduction C oenzyme Q10 (CoQ10) is an important cofactor in the respiratory chain. The reduced form of Coenzyme Q10 (ubiquinol) serves as a potent antioxidant in mitochondria and lipid.
(1) More recently, studies in vitro, (2, 3) in SAMP1 mice (4) and in humans (5) provide evidence that ubiquinol is involved in inflammatory processes and lipid metabolism via gene expression. Moreover, reducing effects of coenzyme Q10 (ubiquinone) have been also described on genes involved in inflammation and hepatic stressassociated processes in the liver of diet-induced obese mice. (6) However, when related to the oxidized form of coenzyme Q10 (ubiquinone), stronger effects have been observed for the reduced form (ubiquinol) both on the transcriptional (4, 7) or protein level (8, 9) in vitro and in vivo. To study the observed transcriptional effects of reduced coenzyme Q10 (ubiquinol) in more mechanistic detail, C57BL6J mice were supplemented for one week with 250 mg/kg BW/d ubiquinol. Afterwards, the resulting gene expression signatures were analyzed in the liver of mice, and DNA methylation patterns within the promoters of regulated genes were evaluated. Epigenetic mechanisms such as DNA methylation have been shown to entail heritable changes in gene expression. (10, 11) Of note, impacts on DNA methylation processes have been already described for various dietary supplements and food nutrients so far. (12, 13) DNA methylation consists of the addition of a methyl group to the fifth carbon-position of the cytosine pyrimidine ring in the context of a CpG dinucleotide. Although most genomic DNA in mammals is deficient in CpG sites, clusters of CpG dinucleotides (CpG islands) were described to be primarily located in promoter regions of genes. (14) Thus, the present study postulates that ubiquinol affects gene expression by modulating DNA methylation patterns in the respective CpG island promoter regions of the selected genes.
Materials and Methods
Animals and diet. C57BL6J mice were reared in the Biochemical and Medical Research Laboratories, KANEKA Corp. (Takasago, Japan), at 22 ± 2°C and a 12 h-light-dark cycle. Water and food intake were available ad libitum. At the beginning of the short-term supplementation study, eight 10-week old male C57BL6J mice were purchased from Charles River Lab. Inc. (Yokohama, Japan). To avoid fighting, mice were housed separately throughout 1-week acclimation period and ubiquinol-supplementation study. In the initial phase of the experiment, C57BL6J mice were randomly assigned to either the ubiquinol (n = 4) or control group (n = 4). Ubiquinol (KANEKA, QH TM ) was added to a standard laboratory mouse diet (powdered CE-2, CLEA, Osaka, Japan) at a concentration of 0.2% with corn oil (1%, v/w). The only corn oil (1%, v/w) was used as a vehicle in the control diet. The mixture was incorporated in pellet-type chow by adding 30% ethanol solution (v/v), pressure shaping and drying. In general, body weights and food consumption of the mice were calculated every second day, while mice were inspected daily. After 7-day supplementation period with ubiquinol or the respective control diet, animals were sacrificed by anesthesia using isoflurane gas. Livers were removed and the outer left lobes were stored in RNAlater Storage Solution (Qiagen, Tokyo, Japan) until use for gene expression and methylation analyses.
Microarray analysis. Microarray analysis was conducted on C four samples for each group, respectively, by using GeneChip kits. After hybridization and washing procedures, microarrays were scanned with the GeneChip ® scanner 3000, using GCOS software. If not stated otherwise, all kits and equipment were purchased from Affymetrix. Fluorescence data were obtained in CEL file format. Quality control and normalization procedure of the files was performed with R software 2.7.1 and BioConductor 2.0.1 provided by the MADMAX database (https:// madmax.bioinformatics.nl). Data were normalized with the GC-RMA algorithm. Only probe sets showing present calls for all arrays at one experimental group (intervention or control) were considered for further analysis. The complete datasets will be submitted to NCBI Gene Expression Omnibus (GEO).
qRT PCR. Primer sequences for real-time quantitative RT-PCR (qRT-PCR) experiments were designed with Primer Express ® Software 3.0 (Applied Biosystems, Darmstadt, Germany). Primer pairs (5'-3') for NELF (forward: GAACCCCGAGCCGAATG, reverse: CCGTTAGGGTTCCCCAGAAT) and GPX3 (forward: ACAGGAGCCAGGCGAGAA, reverse: CCACCTGGTCGAA-CATACTTGA) were obtained from MWG Biotech AG (Ebersberg, Germany). cDNA synthesis was initially carried out with the reverse transcriptase core kit (Eurogentec, Köln, Germany) on a thermocycler (Biometra, Göttingen, Germany). qRT-PCR amplification was performed with the Power SYBR ® Green PCR Master Mix (Applied Biosystems, Darmstadt, Germany) on an Applied Biosystem 7300 qRT-PCR system. Ct-values of target genes were related to those of the corresponding housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Text mining analysis. For analysis of common pathways between regulated genes, Genomatix software 2010 (www. genomatix.de) was used. Probe set IDs of the selected genes were uploaded to BibliospherePathwayEdition (BSPE) software. This text mining tool identifies putative functional connections of genes based on co-citations with transcription factors and other genes in the network from NCBI PubMed. The most stringent co-citation filter restricted to sentences with expert curated information (level B4) was applied.
Promoter DNA methylation analysis. The presence of CpG islands within the ABCA1, ACSL1 and ACYP1 gene promoters was predicted by EMBOSS CpGplot program. Quantitative methylation analysis of the three genes was performed with the MassARRAY ® system (Sequenom, Hamburg, Germany). The MassCLEAVE TM biochemistry was applied after bisulfite treatment of DNA samples and MALDI-TOF mass spectrometry for analyte detection according to the standard protocols recommended by the supplier. Genomic DNA was extracted from mice liver with the DNeasy Kit (Qiagen). One microgram DNA was treated with sodium bisulfate (DNA Bisulfite Treatment Kit, Sequenom, Hamburg, Germany) and target regions of the modified nucleic acid were amplified by PCR using methylation independent primers, designed by the MassARRAY platform specific EpiDesigner software ( Table 2 ). The PCR products were then subjected to in vitro transcription with RNase A cleavage being used for the T-reverse reaction (Sequenom). The generated fragments were displayed based on their molecular weight in the mass spectrum, which was acquired after sample conditioning with a MassARRAY ® Analyzer Compact. The resulting methylation calls were analyzed with EpiTyper Software (Sequenom) to generate quantitative results for each CpG site.
Statistics. If not stated otherwise, data are expressed as means ± SEM of four mice per each group, respectively. Differences between ubiquinol-treated and non-treated animals were analyzed by an unpaired two-tailed Students t test. p values less than or equal to 0.05 were considered as significant.
Results and Discussion
Ubiquinol supplementation reveals no impact on body weight changes. Eight male C57BL6J mice were received at the age of 10 weeks, and initially maintained for 1-week acclimation period. Immediately thereafter, mice were randomly grouped (n = 4 for each group) and either supplemented with ubiquinol (250 mg/kg/d) or a respective control diet for one week. As indicated in Fig. 1 , body weights slightly increased both in the subsequently treated ubiquinol group and in control animals during acclimation period from day 1 (−6) to day 7 (0) from 22.15 ± 0.26 g and 22.68 ± 0.44 g to 22.9 ± 0.29 g (p = 0.0032) and 23.53 ± 0.60 g, respectively. Increases in body weights were obtained during grouping period (from day 0 to day 1) in both groups with total values of 24.43 ± 0.25 g in the ubiquinol group and 24.38 ± 0.11 g in control animals. No significant changes of body weights have been found during supplementation period from day 1 until sacrifice of mice (day 8) both in ubiquinol-treated and control animals. The final body weights were 25.15 ± 0.15 g and 24.73 ± 0.34 for treatment and control animals, respectively, and are thus comparable to age-matched C57BL6J mice described in the literature. (6) Finally, at any indicated time point, no significant differences in body weights were found between treatment and control group. Hence, subsequently described effects of ubiquinol supplementation on gene expression and promoter methylation patterns cannot be simply ascribed to changes in weight.
Whole genome expression data reveal effects of ubiqui nol supplementation on liver lipid metabolism. Microarraybased whole genome expression profiles were analyzed from liver samples of mice either supplemented with ubiquinol (250 mg/kg body weight/d) or a respective control diet for one week. Samples were taken from four mice per each group respectively, resulting in a total of eight microarrays. Differentially expressed genes between ubiquinol-treated and control animals were selected as follows: Initially transcripts with at least four present calls (100%) in one group (treatment or control) were chosen for further analysis. Secondly, transcripts showing at least a 1.5-fold increase or decrease in the ubiquinol-treated animals when related to controls (p≤0.05, Students t test) were selected. Based on these criteria, 1112 and 571 transcripts were up-and down-regulated by ubiquinol, respectively. To study the observed effects of ubiquinol supplementation on gene expression in more detail, transcripts with the highest fold change values ("Top 20", p≤0.05) were selected. However, before unravelling putative functional connections among these genes, the accuracy of microarray data was verified by qRT-PCR for two selected "top 20" genes, namely glutathione peroxidase 3 (GPX3) and nasal embryonic LHRH factor (NELF) (Fig. 2) . In brief, GPX3 has been described to mediate PPARγ-associated antioxidant effects in human muscle cells and plasma. (15) Additionally, an influence on the regulation of local and systemic oxidative stress processes has been described. (16) In this context, effects of ubiquinol supplementation on hepatic oxidative stress-associated gene regulation has been already described previously. (6) The NELF gene is primarily expressed in olfactory sensory cells and LHRH cells during embryonic development, (17) and is therefore ascribed as an important factor in the developmental migration process. In adult tissue, NELF has been also shown to be present in the liver. (17) In summary we could show that the fold change values of the two selected "top 20" genes glutathione peroxidase 3 (GPX3) and nasal embryonic LHRH factor (NELF) (Fig. 2) were in accordance to the microarray data (Table 1) . To determine functional connections between the "top 20" up-and down-regulated genes, text mining analysis was subsequently performed by the use of Genomatix BibliospherePathwayEdition Software including GFG level B4. Based on these stringent criteria, three ubiquinol-sensitive genes [ATPbinding cassette, sub-family A (ABC1), member (ABCA1), stearoyl-Coenzyme A desaturase 1 (SCD1) and glycerol-3-phosphate acyltransferase (GPAM)] were functionally connected with each other in the PPARα signalling pathway (Fig. 3) . Moreover, when related to GeneOntology terms (Table 1) , 6 (15%) of the "top 20" up-and down-regulated genes were related to cholesterol or lipid metabolism. These results suggest a functional role of ubiquinol in cholesterol and/or lipid metabolism and are, inter alia in agreement to a previous performed supplementation study with ubiquinol in senescence accelerated mice prone (SAMP1). In this Table 2 . PCR primers for analysis of the methylation status of (A) ABCA1, (B) ACSL1 and (C) ACYP1 gene promoters. All positions are relative to the entire input sequences study, various genes with a functional role in cholesterol synthesis, fat assimilation and lipoprotein metabolism have been shown to be affected. (4) Moreover, these transcriptional effects were also translated into physiological readouts of cholesterol metabolism in vivo. (18) In summary, our present and previous data show both short and long-term effects of ubiquinol supplementation on genes involved in liver lipid and/or cholesterol metabolism.
Ubiquinol induced effects on gene expression are not mediated by changes in promoter methylation. With regard to the functional analysis of the microarray data from liver tissues of ubiquinol-supplemented mice, distinct effects on genes related to lipid and/or cholesterol metabolism were found (Table 1, Fig. 3 ). Because transcriptional variation has been correlated with CpG island variation (19) and previous literature reports have documented distinct roles of various micronutrients in the epigenetic regulation of gene expression, (20) (21) (22) (23) CpG island regions in promoter regions of three regulated genes strongly related to lipid metabolism were analyzed for putative changes by using base-specific cleavage and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry. In general, as an essential precondition, all three genes show CpG islands in their promoter regions and could be therefore selected for DNA methylation analysis. Based on these criteria and the results from microarray experiments, the following ubiquinol-regulated genes (p≤0.05) were finally selected for subsequent methylation analysis: ABCA1 (ATP-binding cassette, sub-family A, member 1), ACSL1 (Acyl-CoA Synthetase long-chain family member 1) and ACYP1 (Acylphosphatase 1). These genes have been shown to be regulated about +3.14-fold (p≤0.05), −2.13-fold (p≤0.05) and +2.18-fold (p≤0.01), respectively, when related to liver samples of control mice. In brief, the ABCA1 gene is a LXR target gene and plays an important role in reverse cholesterol transport. (24) ACSL1 plays an important role in fatty acid metabolism and triacylglycerol synthesis. (25) Disturbances of these pathways may result in e.g. dyslipidemia, one hallmark of the metabolic syndrome.
(26) ACYP1 primarily mediates hydrolytic activity on e.g. acyl phosphates and aryl phosphate monoesters. (27) Overall, our DNA methylation analysis at 282 (sense orientation) and 271 (antisense orientation) CpG units, spanning nucleotides relatively to the gene start position from −748 to 1,391 for ABCA1 gene (Fig. 4A) , from −552 to 819 for ACSL1 gene (Fig. 4B) , and from −6,863 to -7,663 as well as −298 to 336 for ACYP1 gene (Fig. 4C ) revealed no differences between Q10H2-treated and control animals. From these results, no significant differences in the promoter methylation patterns of ABCA1, ACSL1 and ACYP1 genes could be detected with regard to a short term supplementation period with ubiquinol in C57BL6J mice.
Although we could not found any significant effects of ubiquinol supplementation on CpG island promoter region methylation patterns of ABCA1, ACSL1 and ACYP1 genes, previous results in the literature show that coenzyme Q10 containing coenzyme supplementation is able to induce the disappearance of tamoxifen-induced RASSF1A DNA methylation patterns in breast cancer patients. (28) Moreover, this supplementary therapy has also been shown to counteract the tamoxifen-induced increased lipoprotein and lipid levels in these patients. (28) By the way, ubiquinol-induced reductions of LDL cholesterol levels have been also observed previously in healthy male volunteers. From these results it seems that ubiquinol supplementation may modulate lipid metabolism through an impact on DNA methylation patterns. Although we could not find any ubiquinol-induced supplementary effects in the present study, it can not be ruled out that changes in the methylation pattern other than in the promoter region of ABCA1, ACSL1 and ACYP1 genes have led to the observed differences on gene expression. In fact, effects on global methylation patterns have been already described for several other dietary supplements and micronutrients in the literature. (20, 21, (29) (30) (31) (32) Thus, a global methylation analysis would be required to finally answer the question of a ubiquinol-dependent epigenetic regulation of ABCA1, ACSL1 and ACYP1 genes. Moreover, the observed changes in gene expression might be also mediated through modifications of histones by acetylation, methylation, phosphorylation, ubiquitination, sumoylation or isomerisation. (22, 23) The ability of dietary compounds to influence epigenetic processes via histone modification has been already described in vitro and in vivo. (32, 33) However, the translation of these findings into clinical health applications is still a remaining challenge for further studies in the future.
In summary, we could show that one-week supplementation with ubiquinol (250 mg/kg BW/d) induces a gene expression pattern in liver tissues of C57BL6J mice with a functional role in PPARα signalling, lipid and/or cholesterol metabolism. Because transcriptional variation has been correlated with CpG island variation, CpG island regions in promoter regions of three regulated genes (ABCA1, ACSL1 and ACYP1) with a relevant impact in lipid and/or cholesterol metabolism were analyzed. However, promoter DNA methylation analysis of ABCA1, ACSL1 and ACYP1 promoters in the liver of C57BL6J mice revealed no differences between ubiquinol-treated and control mice. Thus, ubiquinol affects the expression of genes involved in PPARα signalling and lipid metabolism without changes in promoter DNA methylation in the liver of mice.
Acknowledgments
This work was supported by KANEKA Corporation, Japan. The coloured dots indicate the software determined methylation ratio at each analyzed CpG unit for each sample. nc_001 represents the reaction negative control (water) and DNA meth the artificially completely methylated control DNA. The reference sequence above the epigram corresponds to the genomic sequence of the analyzed strand. Displayed is the sense orientation in 5' → 3' direction. Base numbering in the epigram refers to the analyzed amplicon.
